In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.
|Articles|June 29, 2021
Clostridioides Difficile Infection Symposium for Patients, Families, Caregivers
Author(s)Contagion Editorial Team
This event will be a free, virtual event in July with expert speakers and survivors.
Advertisement
The C Diff Foundation announced today it will be hosting an interactive symposium on July 16, from 1 to 3 pm EDT. For providers who have cared for patients who have battled CDI, this event is an opportunity for them to hear from fellow survivors who will share their stories to provide a real-world perspective on the patient experience.
Presenters will include C diff thought leaders including healthcare professionals, practitioners, and educators who are helping to change the way individuals maneuver through a C difficile infection, worldwide.
Other topics addressed will include creating a culture for patient-centered care, C difficile innovations, diagnostics, research, environmental safety, clinical trials, and studies.
To sign-up for the event go
Advertisement
Related to this article
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with Staphylococcus aureus Bacteremia (SAB). This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline.
New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.
Recent urinary tract infection guideline updates from multiple international
medical societies highlight evolving recommendations, including a major shift
in classification, moving from anatomy- and risk factor–based definitions
toward distinguishing localized from systemic infections.
Confirmed US measles cases rose 6.8% this week to 5,182, more than double the 2025 total, as three states reported measles-associated deaths.
Li Tao, PhD, discusses early US uptake of twice-yearly lenacapavir, faster prescription-to-injection timelines, and how ACA coverage milestones tracked with zero cost sharing and HIV diagnoses.
In a target trial emulation using N3C data, adults prescribed metformin within six days of SARS-CoV-2 infection had about half the risk of long COVID or death within six months.
Advertisement
Advertisement
Trending on Contagion Live
1
Measles Update: November 6, 2026
2
A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia
3
Recent Guideline Updates in the Management of Urinary Tract Infections
4
IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
5